Metagenomi Therapeutics, Inc. (MGX) stock
MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$0.63+0.00 (+0.13%)
Close on Nov 18, 2026Market cap $23.87MP/E –Yield –
Metagenomi Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Metagenomi Therapeutics's price to sales ratio was 2.0× on Jul 31, 2026, against 1.9× a year earlier. Over the last 3 years it ranged from 0.5× to 5.1×, with a median of 2.0×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Jul 31, 2026 | 2.0× | +0.0 |
| 2025 | Dec 31, 2025 | 2.0× | −0.5 |
| 2024 | Dec 31, 2024 | 2.5× | – |
See a number that looks wrong?